A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors. - Wikidata - wikimedia - TriplyDB

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.

http://www.wikidata.org/entity/Q35288804

about

Profile of farletuzumab and its potential in the treatment of solid tumors A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles.

P2860

Q26750431-C383E9AD-BBD1-4CAB-B3E7-CDAA4CEE1C41 Q26781856-08B4E5FA-53B5-4C38-BEF2-B3A1EAD0F931 Q38940035-53106D14-7BD3-4DE8-AD15-BD5A3B63035D Q47861842-463AA59C-5D08-4325-A8EF-0FF07C8FA729 Q47926770-1A213ED1-1F9D-44E4-9805-342EE2A4FAF8 Q48234647-2C1B694C-4783-456C-9391-478A1D247F54 Q49226309-C232DA76-56D4-4B64-BDEF-851DE65B88D0

P2860

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.

http://www.wikidata.org/entity/Q35288804

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase I study of farletuzuma ...... in patients with solid tumors.

@ast

A phase I study of farletuzuma ...... in patients with solid tumors.

@en

type

label

A phase I study of farletuzuma ...... in patients with solid tumors.

@ast

A phase I study of farletuzuma ...... in patients with solid tumors.

@en

prefLabel

A phase I study of farletuzuma ...... in patients with solid tumors.

@ast

A phase I study of farletuzuma ...... in patients with solid tumors.

@en

P1433

Q35288804-17E4ABDC-8667-4078-90F3-935FD90BC764

P1476

Q35288804-5B9C8EF5-87F0-48C8-8EAB-9A33E63AB6AD

P2093

Q35288804-2473F63E-43FE-423B-8D35-9ECF4763B0BB

Q35288804-334ACDFA-0EEC-4A75-9B03-F28160F19650

Q35288804-3B9FF4EF-CF5D-4923-B61F-559635E582C3

Q35288804-412FC53B-6759-4009-99DD-45D314FA82F7

Q35288804-4F5CE322-0D3D-4E00-A2DF-5ECB8A437A13

Q35288804-5420D87E-16C7-4374-B8A9-B31549E8BD2F

Q35288804-57FA6E93-071B-47F5-9011-CD1265CF3CD2

Q35288804-5C70D0D4-26BC-4443-A489-6A0386593F0C

Q35288804-7DD9B2C5-8F98-4D62-BA1C-962F3F527624

Q35288804-8C8AA486-B7DA-4B82-9E3D-B48645158476

P2860

Q35288804-2A9CC5FA-2C17-4CE2-964F-101297F90FE0

Q35288804-2E058F6D-4B0B-44B3-8CC7-CB487D495C34

Q35288804-49E69AC3-C995-4519-B7B0-0A79C27C4974

Q35288804-5BD7F884-F7F9-4B4D-B0CC-2BAF1496F99E

Q35288804-89BA9982-9C9B-484D-9B9A-3BDB53084F16

Q35288804-A4A76849-0B57-4789-9036-5C3529796889

Q35288804-A8CE0C14-7358-435A-A1A3-DACC83ED046D

Q35288804-B779DF20-432E-42E9-8CAD-8A06D526E57A

Q35288804-CC5135DD-DBF5-4F5B-94E4-A3D23B8D3B79

Q35288804-D44CBC8C-CB1C-4D19-B714-7BE1D26F9812

P2888

Q35288804-DF646A69-0493-4416-B956-D6D0B716756F

P304

Q35288804-B7C46BD2-589C-48BD-A629-75F93E13C884

P31

Q35288804-70CE1E15-F463-4BF8-BF17-F9ABEF139A83

P356

Q35288804-73B14A20-6F8E-4FBE-BC62-030C94C40113

P433

Q35288804-70E25975-075C-4F4A-BA57-F02591985E0C

P478

Q35288804-2C5F7072-5EB9-4707-B7A4-CAF24C8A480C

P577

Q35288804-6F8C806F-7E12-439B-82E1-B225FF0124A6

P5875

Q35288804-DC12DD1A-61A5-4878-B2A9-57BF61AECCE3

P698

Q35288804-6CC1B655-366B-4B0C-891B-D54A2850BB2A

P932

Q35288804-16F2A630-E6D5-457E-9E3C-6555F245F0A0

P356

S10637-014-0180-8

P1433

Investigational New Drugs

P1476

A phase I study of farletuzuma ...... in patients with solid tumors.

@en

P2093

Hiroo Ishida

http://www.w3.org/2001/XMLSchema#string

Keiichi Fujiwara

http://www.w3.org/2001/XMLSchema#string

Keishi Yamashita

http://www.w3.org/2001/XMLSchema#string

Keisuke Miwa

http://www.w3.org/2001/XMLSchema#string

Ken Shimada

http://www.w3.org/2001/XMLSchema#string

Kosei Hasegawa

http://www.w3.org/2001/XMLSchema#string

Makoto Kodaira

http://www.w3.org/2001/XMLSchema#string

Masayuki Namiki

http://www.w3.org/2001/XMLSchema#string

Minami Matsuda

http://www.w3.org/2001/XMLSchema#string

Noriyuki Katsumata

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Folate-binding protein is a marker for ovarian cancer

The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Overexpression of folate binding protein in ovarian cancers.

Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.

Antibody pharmacokinetics and pharmacodynamics.

P2888

s10637-014-0180-8

P304

332-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-014-0180-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268039376

http://www.w3.org/2001/XMLSchema#string

P698

25380636

http://www.w3.org/2001/XMLSchema#string

P932

4387250

http://www.w3.org/2001/XMLSchema#string